Men with low testosterone will soon have greater access to hormone replacement therapy following new changes to product labeling from the Food and Drug Administration.

The Department of Health and Human Services announced on Thursday that the drug regulating agency would be updating labeling information related to the cancer risks of testosterone replacement, as well as removing cautionary notes on the safety and efficacy of the treatment for age-related low testosterone.